Application of macrophage LSR in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy

By targeting the macrophage LSR gene and protein and promoting its expression and function, the problem that existing treatments are difficult to block the progression of diabetic nephropathy is solved, efficient individualized treatment and early diagnosis are achieved, and the treatment effect is significantly improved.

CN120714042APending Publication Date: 2025-09-30BINZHOU MEDICAL COLLEGE
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202510898107.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-01
Publication Date
2025-09-30

AI Technical Summary

Technical Problem

Existing treatments for diabetic nephropathy are unable to effectively block disease progression, and some patients cannot avoid disease worsening. New therapeutic strategies targeting macrophages are urgently needed.

Method used

By targeting the macrophage LSR gene and/or LSR protein to promote its expression and function, using nucleic acid molecules, carbohydrates, lipids, small molecule chemical drugs, antibody drugs, peptides, proteins or viruses and other substances to regulate signal pathways, enhance the expression and activity of LSR, and develop various intervention strategies such as gene transfection, viral vector delivery and signal pathway regulation.

Benefits of technology

It significantly improves the treatment effect of diabetic nephropathy, reduces the risk of adverse events, provides personalized treatment plans, improves medication compliance, supports early diagnosis, and delays disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120714042A_ABST
    Figure CN120714042A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine, and particularly relates to application of macrophage LSR gene and / or LSR protein in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy. Research finds that the LSR deletion of macrophages aggravates renal injury by promoting inflammatory response of diabetic nephropathy and increasing lipid renal toxicity; on the contrary, after the LSR expression of the macrophages is recovered, the inflammatory response and lipid droplet deposition of the kidney of the diabetic nephropathy mouse can be effectively reduced, and meanwhile, the kidney injury is improved. Cell experiments show that LSR deletion of macrophages can activate a YAP signal channel to increase secretion of inflammatory factors and reduce low-density lipoprotein uptake at the same time. Therefore, the macrophage LSR can be used as a diabetic nephropathy drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the use of macrophage LSR genes and / or LSR proteins in the preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy. Background Art

[0002] Diabetic nephropathy (DN), one of the most common microvascular complications of diabetes, has become a leading cause of chronic kidney disease (CKD) in urban tertiary hospitalized patients in my country, ultimately leading to end-stage renal disease (ESRD), which may require dialysis or renal transplantation in advanced stages. The characteristic pathological feature of the renal structure in DN is macrophage infiltration, which exhibits significant heterogeneity, primarily consisting of tissue-resident and circulating macrophages. These macrophages contribute to the development and progression of diabetic nephropathy through multiple pathways. They can directly drive the progression of diabetic nephropathy by secreting proinflammatory cytokines, triggering a persistent inflammatory response in the kidney. Furthermore, the multiple lipoprotein receptors expressed on their surface recognize and uptake lipoprotein particles, playing a central role in maintaining local lipid homeostasis in the kidney, thereby effectively protecting podocytes and renal tubular epithelial cells from lipotoxic damage. While current treatments (such as blood sugar and blood pressure control and RAS inhibitors) can slow progression, some patients still cannot avoid disease progression, necessitating the urgent need for therapeutic strategies targeting novel pathological mechanisms. Therefore, developing new therapeutic strategies targeting macrophage lipoprotein receptors to treat diabetic nephropathy has become an important direction to break through the current clinical bottleneck. Summary of the Invention

[0003] In order to solve the problems existing in the prior art, the purpose of the present invention is to provide a treatment plan targeting macrophage LSR, which can intervene in the course of diabetic nephropathy by promoting the expression of LSR in macrophages, inhibiting the secretion of inflammatory factors and promoting the uptake of lipoprotein particles.

[0004] In order to achieve the purpose of the present invention, the technical solution of the present invention is as follows: In the first aspect, the present invention provides the use of macrophage LSR gene and / or LSR protein in the preparation or screening of drugs for preventing, alleviating, assisting in the treatment or / and treating diabetic nephropathy.

[0005] In a second aspect, the present invention provides the use of a macrophage LSR gene and / or LSR protein promoter in the preparation of a drug for preventing, alleviating, assisting in the treatment or / and cure of diabetic nephropathy.

[0006] Furthermore, the promoter is a substance that can enhance the expression and / or activity and / or function of the LSR gene and / or LSR protein.

[0007] Furthermore, the LSR protein promoter includes substances that target and regulate the expression and / or activity of LSR genes and / or proteins by regulating signal pathways.

[0008] Furthermore, the LSR gene expression promoter is one or more combinations of nucleic acid molecules, carbohydrates, lipids, small molecule chemical drugs, antibody drugs, polypeptides, proteins or viruses that can upregulate the expression of LSR genes and / or proteins.

[0009] Furthermore, the recombinant expression vector includes any one of a vector-based eukaryotic expression plasmid, adenovirus, adeno-associated virus, lentivirus, retrovirus, baculovirus, herpes virus, pseudorabies virus, LNP liposome, microinjection technology, gene editing system elements or homologous recombination vector that specifically targets the LSR gene.

[0010] In a third aspect, the present invention provides a drug comprising the aforementioned LSR gene and / or LSR protein, or at least one of the aforementioned LSR gene and / or LSR protein expression promoters, as the main functional component of the drug.

[0011] Furthermore, the drug also includes pharmaceutically acceptable excipients, which include at least one of diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, and lubricants. The drug is in the form of any of tablets, capsules, powders, pills, granules, solutions, suspensions, syrups, injections, suppositories, inhalants, and sprays.

[0012] Furthermore, the mass percentage of the functional component in the medicine is 1%-99%.

[0013] In a fourth aspect, the present invention provides the use of a reagent for detecting the expression level of LSR gene and / or protein in macrophages in the preparation of a product for the diagnosis, screening or evaluation of diabetic nephropathy.

[0014] Furthermore, the product includes any one of a chip, a diagnostic reagent, and a diagnostic kit; the detection sample of the product is any one of a cell or whole blood; the product contains an antibody that specifically binds to the LSR protein or a peptide segment of the LSR protein, or contains primers that specifically amplify the LSR gene, or contains a probe that specifically detects the LSR gene.

[0015] The beneficial effects of the present invention are:

[0016] (1) The present invention is the first to discover that regulating the expression level of LSR in macrophages can effectively promote the low-density lipoprotein uptake function of macrophages and inhibit the secretion of inflammatory factors. Compared with traditional treatment methods that only target superficial symptoms such as renal inflammation or fibrosis, the present invention blocks disease progression at the cell biology and molecular biology levels, reduces the risk of adverse events of diabetic nephropathy, significantly improves the treatment effect of the disease, and provides a more efficient solution for clinical treatment.

[0017] (2) The present invention provides a variety of intervention strategies to promote macrophage LSR expression, which can be flexibly selected based on the patient's individual genetic background, disease progression stage, and actual clinical medical conditions. For example, for patients with critical conditions, viral vector-mediated gene transfection technology can be used to quickly achieve efficient expression of the LSR gene; for patients seeking low toxic side effects, functional expression agonists of macrophage LSR can be used to target and regulate related signaling pathways. This diversified treatment strategy significantly improves the clinical adaptability of the treatment plan and provides an effective means to achieve personalized and precise treatment of diabetic nephropathy.

[0018] (3) The present invention uses the macrophage LSR gene and its encoded protein as a novel drug target, opening up a new direction for the development of diabetic nephropathy drugs. The functional expression agonist developed based on this target has the significant advantages of high specificity and low toxic side effects. Combined with a variety of dosage forms such as tablets, capsules, and injections, personalized dosing regimens can be formulated according to the patient's medication habits, which helps improve the patient's medication compliance and provides more high-quality options for the drug treatment of diabetic nephropathy.

[0019] (4) The present invention provides a chip, diagnostic reagent, or kit for the preparation of an auxiliary diagnosis for diabetic nephropathy that targets the macrophage LSR gene or protein. This discovery facilitates early diagnosis of the disease, enabling patients to receive targeted treatment in the early stages of the disease, thereby effectively delaying disease progression. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The following is the result of the detection of LSR gene expression in peritoneal macrophages of mice after high glucose treatment: Figure 1 A shows the expression changes of LSR mRNA level in peritoneal macrophages of mice after high glucose treatment, and B and C show the expression changes and gray value statistics of LSR protein level in peritoneal macrophages of mice after high glucose treatment;

[0021] Figure 2 The results of the LSR gene expression test in human THP-1 macrophages after high glucose treatment are as follows: Figure 2A in the middle shows the expression changes of LSR mRNA level after high glucose treatment in human THP-1 macrophages; B and C show the expression changes and gray value statistics of LSR protein level after high glucose treatment in human THP-1 macrophages;

[0022] Figure 3 The subcellular localization of LSR in macrophages, the separation and localization analysis of macrophage components showed that LSR was localized on the macrophage cell membrane. Immunofluorescence staining of mouse and human macrophages also proved that LSR was a macrophage cell membrane localized molecule.

[0023] Figure 4 Compared with control mice, the protein / urine creatinine ratio of diabetic nephropathy mice lacking macrophage LSR was significantly increased;

[0024] Figure 5 Immunofluorescence staining showed that the expression levels of podocyte marker proteins NPHS1, NPHS2, PODXL and WT1 in diabetic nephropathy mice with macrophage LSR deficiency were significantly lower than those in the control group;

[0025] Figure 6 The following are the histological staining and electron microscopic results of glomeruli in normal and macrophage LSR-deficient diabetic nephropathy mice. Compared with the control group, macrophage LSR-deficient diabetic nephropathy mice showed significant glomerular hypertrophy, mesangial matrix deposition, GBM thickening, and fusion and disappearance of foot processes.

[0026] Figure 7 The creatinine content in the serum of diabetic nephropathy mice was significantly increased in the absence of macrophage LSR compared with the control group.

[0027] Figure 8 The results showed that compared with control mice, the absence of macrophage LSR led to a significant increase in the mRNA and protein levels of the kidney injury molecules KIM-1 and NGAL, as well as the kidney fibrosis molecule a-SMA in diabetic nephropathy mice.

[0028] Figure 9 Histological staining of normal and macrophage LSR-deficient diabetic nephropathy mice. The results showed that macrophage LSR deficiency led to aggravated renal fibrosis in diabetic nephropathy mice.

[0029] Figure 10 Immunofluorescence staining showed that compared with the control group, the expression of renal fibrosis molecules a-SMA and Collagen Ⅰ in diabetic nephropathy mice with macrophage LSR deficiency was significantly increased;

[0030] Figure 11The results are shown in Figure 2. Serum LDL-C levels and glomerular oil red staining of normal and macrophage LSR-deficient diabetic nephropathy mice. The results show that macrophage LSR-deficient diabetic nephropathy mice lead to a significant increase in serum LDL-C levels and increased glomerular lipid droplet accumulation.

[0031] Figure 12 Oil red staining of renal tubules of normal and diabetic nephropathy mice with macrophage LSR deficiency. The results showed that macrophage LSR deficiency in diabetic nephropathy mice led to increased accumulation of renal tubular lipid droplets.

[0032] Figure 13 Compared with control mice, diabetic mice lacking macrophage LSR had a significantly lower protein / urine creatinine ratio after receiving wild-type mouse bone marrow transplantation;

[0033] Figure 14 Immunofluorescence staining showed that compared with the control group, the expression levels of podocyte marker proteins NPHS1, NPHS2, PODXL and WT1 were significantly increased in diabetic mice with macrophage LSR deficiency after receiving wild-type mouse bone marrow transplantation;

[0034] Figure 15 The histological staining and electron microscopy results of bone marrow transplanted mice showed that compared with the control group, the diabetic mice lacking macrophage LSR showed no significant increase in glomerular volume after receiving wild-type mouse bone marrow transplantation, the mesangial matrix was evenly distributed without obvious abnormal deposition, the GBM thickness was uniform, and the podocyte structure was clear and regularly arranged;

[0035] Figure 16 The results showed that compared with the control group, the serum creatinine level of diabetic mice lacking macrophage LSR after receiving wild-type mouse bone marrow transplantation was significantly reduced, and renal tubular damage was alleviated.

[0036] Figure 17 The results showed that compared with control mice, the mRNA and protein levels of kidney injury molecules KIM-1 and NGAL, as well as kidney fibrosis molecule a-SMA, were significantly reduced in diabetic mice with macrophage LSR deficiency after receiving wild-type mouse bone marrow transplantation, and kidney injury and renal fibrosis were alleviated.

[0037] Figure 18 Masson staining results of the kidneys of bone marrow transplanted mice showed that compared with control mice, renal fibrosis was alleviated in diabetic mice lacking macrophage LSR after receiving wild-type mouse bone marrow transplantation.

[0038] Figure 19The results of immunofluorescence staining of renal fibrosis molecules in bone marrow transplanted mice show that compared with the control group, the expression of renal fibrosis molecules a-SMA and Collagen Ⅰ in diabetic mice lacking macrophage LSR after receiving bone marrow transplantation from wild-type mice was significantly reduced, and renal fibrosis was alleviated.

[0039] Figure 20 Serum LDL-C levels and glomerular oil red staining were performed after bone marrow transplantation in diabetic nephropathy mice. The results showed that serum LDL-C levels in diabetic nephropathy mice that lacked macrophage LSR and received bone marrow transplantation from wild-type mice were significantly reduced, and the accumulation of lipid droplets in the glomeruli was also reduced.

[0040] Figure 21 Oil red staining of renal tubules in diabetic nephropathy mice after bone marrow transplantation. The results showed that the accumulation of lipid droplets in the renal tubules of diabetic nephropathy mice that lack macrophage LSR was reduced after receiving bone marrow transplantation from wild-type mice.

[0041] Figure 22 LSR deficiency in bone marrow-derived macrophages leads to a pro-inflammatory response by activating the YAP signaling pathway, specifically, LSR deficiency in bone marrow-derived macrophages leads to increased YAP protein expression and decreased p-YAP protein expression ( Figure 22 A) Increased expression of YAP target genes Cyr61, Edn1, Ctgf, and pro-inflammatory cytokines ( Figure 22 B);

[0042] Figure 23 LSR deficiency in peritoneal macrophages leads to a proinflammatory response by activating the YAP signaling pathway, specifically, LSR deficiency in peritoneal macrophages leads to increased YAP protein expression and decreased p-YAP protein expression ( Figure 23 A) Increased expression of YAP target genes Cyr61, Edn1, Ctgf, and pro-inflammatory cytokines ( Figure 23 B);

[0043] Figure 24 LSR deficiency in renal resident macrophages leads to a proinflammatory response by activating the YAP signaling pathway, specifically, LSR deficiency in renal resident macrophages leads to increased YAP protein expression and decreased p-YAP protein expression ( Figure 24 A) Increased expression of YAP target genes Cyr61, Edn1, Ctgf, and pro-inflammatory cytokines ( Figure 24 B);

[0044] Figure 25 The changes in Dil fluorescence values ​​in the liver, kidney and serum of mice 4 hours after Dil-LDL was injected into the tail vein are as follows: Figure 25A: 4 hours after the tail vein injection of Dil-LDL, the Dil fluorescence value in the liver of KO mice was significantly increased compared with that of the control group. Figure 25 B shows that the Dil fluorescence value in the kidney of KO mice was significantly increased compared with the control group 4 hours after the tail vein injection of Dil-LDL. Figure 25 C is the residual Dil fluorescence value in the serum of KO mice injected with Dil-LDL in the tail vein 4 hours later, which was significantly higher than that in the control group. Figure 25 D is a representative image of Dil-LDL deposition in the liver and kidney 4 hours after Dil-LDL injection (scale bars: 20 μm and 50 μm);

[0045] Figure 26 Representative images of Dil-LDL deposition in PMs and BMDMs after macrophages were treated with 20 μg / ml Dil-LDL for 4 hours ( Figure 26 AB), quantification of Dil-LDL in cell lysates and culture medium of PMs and BMDMs ( Figure 26 CD);

[0046] Figure 27 Quantification of Dil-LDL in cell lysates and culture medium after 4 h of treatment with 20 μg / ml Dil-LDL in THP-1 cells after LSR overexpression and knockdown;

[0047] Figure 28 Representative images of macrophage LSR mediating LDL internalization in a clathrin-dependent manner;

[0048] Figure 29 This is an experimental verification diagram provided by the present invention that reveals that macrophage LSR is used as a target to intervene in the course of diabetic nephropathy. DETAILED DESCRIPTION

[0049] In order to more clearly understand the above-mentioned objectives, features and advantages of the present invention, the scheme of the present invention will be further described below. It should be noted that, in the absence of conflict, the embodiments of the present invention and the features therein can be combined with each other.

[0050] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein; it is obvious that the embodiments in the specification are only part of the embodiments of the present invention, rather than all the embodiments.

[0051] The preferred embodiments of the present invention will be described in detail below with reference to the examples. It should be understood that the following examples are provided for illustrative purposes only and are not intended to limit the scope of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention.

[0052] 1. Definition

[0053] In this specification, the expressions “comprise” and “include” include concepts such as “comprise”, “include”, “consist essentially of” and “consist only of”.

[0054] "Homology" of a nucleotide sequence refers to the degree of identity of two or more nucleotide sequences that can be compared relative to each other's nucleotide sequences. Therefore, the higher the identity of two nucleotide sequences, the higher the identity or similarity of these sequences. The level of identity of a nucleotide sequence can be determined, for example, using FASTA, a tool for sequence analysis, using default parameters. Alternatively, it can be determined using the BLAST algorithm based on Karlin and Altschul. A program called BLASTX based on such a BLAST algorithm has been developed. The specific methods of these analytical methods are well known and can be found on the website (http: / / www.ncbi.nlm.nih.gov / ) of the National Center of Biotechnology Information (NCBI).

[0055] In this specification, the abbreviation "LSR" refers to the protein.

[0056] The present invention relates to a recombinant expression vector comprising an LSR gene expression regulatory region and a gene configured to be expressed under the control of the region. A "recombinant expression vector" refers to a polynucleotide capable of expressing the gene contained in the expression vector in a cell (e.g., a eukaryotic cell, preferably an animal cell, more preferably a mammalian cell). The type of vector is not particularly limited and may include any of a vector-based eukaryotic expression plasmid, adenovirus, adeno-associated virus, lentivirus, retrovirus, baculovirus, herpes virus, pseudorabies virus, LNP liposome, an expression vector constructed by microinjection technology, a gene editing system component, or a homologous recombination vector that specifically targets the LSR gene.

[0057] The vector of the present invention may also be contained within a cell. Such cells (hereinafter referred to as "cells of the present invention") are also included in the present invention. In the cells of the present invention, the vector of the present invention may exist outside the genome or may exist in a state of being incorporated into the genome.

[0058] LSR genes derived from various animals are known, and examples of LSR proteins that are their expression products include the following:

[0059] The human LSR gene sequence is shown in SEQ ID No: 1 to SEQ ID No: 6, and the corresponding human LSR gene amino acid sequence is shown in PROTEIN ID NP_001372144.1 (SEQ ID No: 7), PROTEIN ID NP_001372144.1 (SEQ ID No: 8), PROTEINID NP_001372144.1 (SEQ ID No: 9), PROTEINID NP_001372144.1 (SEQ ID No: 10), PROTEIN ID NP_001372144.1 (SEQ ID No: 11), and PROTEIN ID NP_001372144.1 (SEQ ID No: 12).

[0060] The LSR protein of the present invention can be a naturally occurring protein or can be produced as a recombinant protein using genetic recombination techniques. Naturally occurring proteins can be produced by affinity chromatography using antibodies against the LSR protein, using extracts from macrophages expressing the LSR protein. Of course, recombinant proteins can be produced by culturing cells transformed with DNA encoding the LSR protein.

[0061] The LSR gene expression promoters of the present invention are one or more combinations of compounds, polypeptides, proteins, nucleic acids and nucleic acid aptamers, natural active substances, and biological agents that can upregulate LSR gene and / or protein expression. LSR protein promoters include substances that target and regulate LSR gene and / or protein expression and / or activity by modulating signaling pathways. The presence or absence of promoter activity can be determined according to known methods or the methods described in the Examples.

[0062] In specific implementations, promoting LSR expression in macrophages can be achieved through a variety of technical pathways:

[0063] (1) Gene transfection technology: construct a eukaryotic expression plasmid vector targeting the LSR gene, use liposomes and other transfection reagents, and introduce the vector into the macrophage culture system (37°C, 5% CO2 environment) according to standard operating procedures to achieve intracellular expression of the LSR gene.

[0064] (2) Viral vector-mediated delivery: Gene delivery is performed using viral vector systems such as adenovirus, adeno-associated virus, and lentivirus. Taking lentivirus as an example, the LSR gene vector construction, 293T cell packaging, and macrophage infection processes must be completed in sequence to achieve stable integration and expression of the LSR gene. Special vectors such as baculovirus and herpes virus can be differentiated according to their infection characteristics.

[0065] (3) Novel delivery systems and gene editing: Lipid nanoparticles (LNP), gene editing system components (such as the CRISPR / Cas9 system), and homologous recombination vectors are all optional technologies. When using the CRISPR / Cas9 system, it is necessary to design specific sgRNA for the LSR gene regulatory region and co-transfect it with the Cas9 protein or expression vector to achieve enhanced gene expression. Microinjection technology directly delivers LSR gene nucleic acid solution or LSR protein agonist into macrophages to rapidly increase LSR expression levels.

[0066] (4) Signal pathway regulation: Screening substances that target and regulate LSR expression and / or activity, activating signal pathways that promote LSR expression, or inhibiting signal pathways that negatively regulate LSR expression, to achieve upregulation of expression at the transcriptional and translational levels.

[0067] The pharmaceutical composition and / or auxiliary pharmaceutical composition provided by the present invention comprises a functional expression agonist capable of promoting LSR expression in macrophages, as well as pharmaceutically acceptable active ingredients and excipients. Among them, the active ingredients capable of promoting LSR expression in macrophages include nucleic acid molecules encoding LSR genes, small molecule compounds that upregulate LSR expression, macromolecular bioactive substances (such as polypeptides, proteins, nucleic acid aptamers), and biological preparations, and can be rationally formulated according to needs.

[0068] In the present invention, the term "pharmaceutically acceptable" refers to any molecular entity or composition that does not produce adverse, allergic or other inappropriate or unwanted reactions when administered to an individual. As used herein, the term "pharmaceutically acceptable composition" is synonymous with "pharmaceutical composition" and refers to a therapeutically effective concentration of an active ingredient (e.g., any therapeutic compound disclosed herein). The pharmaceutical compositions disclosed herein can be used for medical and veterinary applications. The pharmaceutical composition can be administered to an individual alone or in combination with other supplementary active ingredients, agents, drugs, or hormones.

[0069] The pharmaceutical composition disclosed in the present invention may optionally include a pharmaceutically acceptable carrier that facilitates the active ingredient to be processed into a pharmaceutically acceptable composition. When used herein, the term "pharmacologically acceptable carrier" is synonymous with "pharmaceutical carrier" and refers to any carrier that does not substantially have long-term or permanent adverse effects when administered, and includes terms such as "pharmacologically acceptable carriers, stabilizers, diluents, additives, adjuvants or excipients". This carrier is typically mixed with the active compound, or allows dilution or encapsulation of the active compound, and can be a solid, semi-solid or liquid reagent. It is understood that the active ingredient can be soluble or can be delivered as a suspension in the desired carrier or diluent. Any of a variety of pharmaceutically acceptable carriers can be used, including but not limited to aqueous media such as water, saline, glycine, hyaluronic acid, etc.; solid carriers such as mannitol, lactose, starch, magnesium stearate, saccharin sodium, talc, cellulose, glucose, sucrose, magnesium carbonate, etc.; solvents; dispersion media; coatings; antibacterial and antifungal agents; isotonic and absorption delaying agents; or any other inactive ingredients. The pharmacologically acceptable carrier may be selected based on the intended mode of administration. Except insofar as any pharmacologically acceptable carrier is incompatible with the active ingredient, its use in a pharmaceutically acceptable composition is contemplated.

[0070] The pharmaceutical compositions disclosed herein may optionally contain, but are not limited to, other pharmaceutically acceptable components (or pharmaceutical components), including but not limited to buffers, preservatives, isotonicity regulators, salts, antioxidants, osmotic pressure regulating agents, physiological substances, pharmacological substances, fillers, emulsifiers, wetting agents, sweeteners or flavoring agents, etc. Various buffers and means for adjusting pH can be used to prepare the pharmaceutical compositions disclosed herein, provided that the resulting formulation is pharmaceutically acceptable.

[0071] In addition, the present invention also provides the use of a reagent for detecting the expression level of LSR gene and / or protein in macrophages in the preparation of a product for auxiliary diagnosis, screening or evaluation of diabetic nephropathy.

[0072] This product uses a variety of detection methods, such as qRT-PCR, in situ hybridization, Northern Blot, Western Blot, chips, high-throughput sequencing platforms, immunohistochemistry or enzyme-linked immunosorbent assay and other technologies to accurately detect the expression level of LSR genes or proteins in samples. The product contains antibodies (including monoclonal antibodies, polyclonal antibodies or single-domain antibodies) that specifically bind to LSR proteins or peptides of LSR proteins, or contains primers that specifically amplify LSR genes, or contains probes that specifically detect LSR genes. The test samples can be cells, tissues or blood, and the product can be in the form of chips, diagnostic reagents or kits. This type of detection product can provide a basis for the early diagnosis and disease assessment of diabetic nephropathy, help clinicians develop individualized diagnosis and treatment plans, and improve the efficiency and quality of disease diagnosis and treatment.

[0073] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0074] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0075] Example 1

[0076] Changes in LSR expression in macrophages after high glucose treatment.

[0077] 1. Culture and grouping of mouse and human macrophages

[0078] (1) Cultivation of macrophages: Macrophages were cultured in a 37°C, 5% CO2 incubator. Fresh 37°C culture medium was replaced every two days. When the cell density reached an appropriate density, the cells were washed with PBS buffer and replaced with 37°C 1640 culture medium. The cells were then cultured in a 37°C, 5% CO2 incubator.

[0079] (2) Model group: After the macrophages were differentiated and matured in a 37°C incubator, the macrophages with good growth status were washed with PBS buffer and replaced with NG, HM, and HG culture media respectively. After 24 hours of stimulation, RNA and protein samples were collected and Western Blot and qRT-PCR were used to detect the expression changes of LSR. The sugar content of the three culture media is as follows: normal sugar group (11mM), high sugar group (40mM glucose), and osmotic pressure control group (40mM mannitol).

[0080] (3) THP-1 cell differentiation induction process: THP-1 cells were routinely cultured in suspension in RPMI-1640 medium containing 10% FBS to maintain the undifferentiated monocyte state. Phorbol methyl paraformaldehyde (PMA, concentration: 100 nM) was then added to induce differentiation for 48 hours. The PMA was then removed and the culture medium was replaced with fresh medium. The cells were then cultured for 24 hours to allow them to adhere and differentiate into macrophage-like morphologies.

[0081] 2. RNA Extraction and Real-time Quantitative PCR

[0082] The cells were homogenized in Trizol (Ambion, USA) to obtain total RNA. RNA was reverse transcribed using a reverse transcription system kit according to the manufacturer's instructions (Takara, Japan). Fluorescence quantitative PCR was then performed using a Thermo Fisher QS3 PCR instrument according to the instructions in the SYBR Green PCR Master Mix (ABI, USA) kit. The internal reference gene was β-actin, and the expression of the ΔCT=Ct was determined based on the ΔCT=Ct. gene -Ct β-actin Calculate the relative expression level of each target gene mRNA and use 2 -ΔCt Value representation.

[0083] 3. Western blot

[0084] (1) Sample preparation

[0085] Cultured macrophages were harvested, rinsed with PBS, and then trypsinized. The reaction was terminated by adding serum-containing medium and the cells were collected by centrifugation. RIPA lysis buffer containing inhibitors was added and the cells were lysed on ice for 30 minutes with vortexing. The supernatant was collected by centrifugation and the protein concentration was determined using a BCA kit.

[0086] (2) Protein separation

[0087] Prepare separation gel and stacking gel according to the molecular weight of the target protein. Mix the protein sample with SDS loading buffer and boil for denaturation. Add 30μg of sample and protein marker to each well. First, electrophorese at 80V until the protein flows into the separation gel, then adjust to 120-150V until the bromophenol blue reaches the bottom.

[0088] (3) Transfer

[0089] Activate and equilibrate the PVDF membrane. Assemble the transfer apparatus in order, ensuring there are no bubbles. Transfer the membrane at a constant voltage of 100 V for 1 hour.

[0090] (4) Subsequent testing

[0091] The membrane was blocked with 5% skim milk or BSA for 1 hour. After washing with TBST, the membrane was incubated with the primary antibody overnight at 4°C and then with the secondary antibody for 1 hour at room temperature. After each incubation, the membrane was washed three times with TBST. ECL luminescent solution was prepared for color development, and images were exposed using a chemiluminescence imager. The grayscale values ​​of the bands were analyzed using Image J, and the relative expression level of the target protein was calculated.

[0092] 4. Data Analysis

[0093] The experimental data were statistically analyzed using Prism 8 software. Unpaired t-test was used and the results were expressed as mean ± standard error of the mean (SEM). P < 0.05 was considered statistically significant.

[0094] 5. Experimental results

[0095] Compared with the control group, the results of real-time fluorescence quantitative PCR and Western blotting showed that high glucose treatment of macrophages could significantly inhibit the expression of LSR ( Figure 1 and Figure 2 The above results indicate that high glucose environment may affect the function of macrophages by downregulating the expression of LSR, thereby participating in the process of diabetes.

[0096] Example 2

[0097] Subcellular localization of LSR in macrophages.

[0098] 1. Protein fraction separation

[0099] The QIAGEN Qproteome Cell Fractionation Kit is used to extract subcellular fractions from macrophages as follows: First, cells are collected and washed, and the supernatant is discarded after centrifugation. Cells are then resuspended in CE1 buffer, vortexed for 15 seconds, and ice-cooled for 10 minutes. The supernatant is then centrifuged at 1,000 g for 10 minutes to obtain the cytoplasmic protein fraction. CE2 buffer is then added to the pellet, vortexed, and ice-cooled for 30 minutes. The supernatant is then centrifuged at 6,000 g for 10 minutes to obtain the membrane protein fraction. Finally, the remaining pellet is treated with CE3 buffer, vortexed and ice-cooled for 30 minutes, and centrifuged at 12,000 × g for 10 minutes. The supernatant is the nuclear protein fraction. Each fraction can be quantified using the BCA assay, and purity verified by Western blotting (e.g., GAPDH is used as a cytoplasmic marker, F4 / 80 as a membrane marker, and Histone H3 as a nuclear marker). All experiments should be performed on ice, and protease inhibitors should be added to prevent degradation.

[0100] 2. Immunofluorescence Staining

[0101] Cell slides were fixed with 4% paraformaldehyde for 15 minutes, washed with PBS, and permeabilized with 0.5% Triton X-100 for 10 minutes. The slides were then blocked with 1% BSA for 1 hour at room temperature, followed by incubation with LSR primary antibody at 4°C overnight. The following day, the slides were washed three times with PBS and incubated with a fluorescently labeled secondary antibody for 1 hour in the dark. Finally, the slides were stained with DAPI for 5 minutes, and the slides were mounted for observation under a fluorescence microscope. The experiment was performed in the dark, and negative controls were included to ensure specificity.

[0102] 3. Experimental Results

[0103] like Figure 3 As shown, both subcellular localization and immunofluorescence staining results showed that LSR was localized on the cell membrane of macrophages.

[0104] Example 3

[0105] Macrophage LSR deficiency leads to aggravated renal damage in diabetic nephropathy mice.

[0106] 1. Construction of experimental animal models

[0107] (1) Unilateral nephrectomy in mice: 8-week-old male wild-type mice and KO mice were randomly divided into groups according to the experimental arrangement, with no less than 10 mice in each group. Then, unilateral nephrectomy was performed, and the specific operation was as follows: the mouse was anesthetized. After the mouse no longer responded to stimulation, which was considered successful anesthesia, the mouse was fixed in a constant temperature metal bath with its back facing up; the hair in the kidney area on the left side of the mouse's back was removed, and after disinfection with a cotton swab smeared with iodine, the skin was cut layer by layer at a 45° angle below the costal spine point. The incision was pulled with surgical forceps to expose the internal organs. The pinkish color was the kidney. The kidney was pulled out by pulling the perirenal fat with forceps to expose it to the external environment; the left kidney was fixed with curved forceps, and the perirenal fat and connective tissue were carefully peeled off with surgical forceps to expose the renal pedicle and ureter; the adrenal gland was freed and returned to the body, and the renal pedicle and ureter were clamped separately with vascular clamps. After ligating the proximal segment, the renal pedicle and ureter were cut at the distal segment and the vascular clamps were removed; the left kidney was removed, and after suturing the wound layer by layer, levofloxacin antibiotics and 200μl saline were injected intraperitoneally, the wound was disinfected, and the mouse was placed in a cage after waking up.

[0108] (2) STZ injection: One week after recovery from unilateral nephrectomy, mice were intraperitoneally injected with STZ (50 mg / kg) in five divided injections. The mice were fasted for 12 hours before the first injection and for 6 hours before the next four injections.

[0109] (3) STZ modeling results: After one week, the mice were fasted for 8 hours and then their blood glucose levels were measured. A blood glucose level above 16.7 mmol / L indicated a successful model. Urine was collected during the corresponding time period and stored for subsequent testing.

[0110] 2. Sample collection and basic data testing

[0111] (1) Urine sample collection: Collect mouse urine, the urine volume should be no less than 0.2 ml

[0112] (2) Kidney specimen collection: The mouse was anesthetized with isoflurane, an inhaled anesthetic, and fixed on the operating table. A 1 ml syringe was used to collect blood specimens from the right ventricle. The right atrial appendage of the mouse was then cut open, and the kidney was perfused with PBS buffer at the apex of the heart. Part of the renal cortex was taken and cut into 1 mm 3 The tissue blocks were fixed in electron microscope solution; 1 / 2 of the kidney tissue was cut and placed in OCT embedding medium and light microscope solution respectively. After the cortex and medulla of the remaining kidney tissue were separated, the cortex was quickly frozen in liquid nitrogen and stored in a -80℃ refrigerator.

[0113] (3) Urine albumin / creatinine (uACR) test: The collected urine sample is tested for urine albumin and creatinine values

[0114] (4) Euthanasia is performed after kidney tissue is collected at the end of observation.

[0115] 3. Isolation of Mouse Glomeruli

[0116] Mice were anesthetized and fixed. After adequate exposure, blood was collected from the right ventricle using a syringe. The right atrial appendage was opened and perfused from the apex with PBS containing iron powder. The kidneys were then quickly separated and placed on ice. The renal capsule was gently removed. The renal cortex was retained and minced, transferred to a 1.5 ml sterile EP tube, and 1 ml of 3 mg / ml collagenase and 1 μl of DNase were added. Digestion was performed in a 37°C incubator for 30 minutes, and the digestion was terminated by adding culture medium. The tissue was then placed through a 100 μm cell sieve and triturated with a sterile tissue grinder. The tissue and sieve were then rinsed repeatedly with PBS, and the tissue fluid was collected into a sterile culture dish. The sieve was replaced with a new one, and the above steps were repeated. The resulting tissue fluid was centrifuged at 3000 rpm for 10-15 minutes, and the supernatant was discarded. The tissue pellet was resuspended in 2 ml of PBS and placed on a magnetic rack for adsorption. The supernatant was discarded, and the glomerular pellet was gently rinsed three times with PBS. The glomerular pellet was then centrifuged at 3000 rpm for 10 minutes.

[0117] 4. Detection indicators

[0118] Real-time fluorescence quantitative PCR, immunoblotting and immunofluorescence staining were used to detect marker proteins in tissue samples, and tissue samples were subjected to histological staining and electron microscopy photography.

[0119] 5. Statistical Analysis

[0120] Cell experiments were performed at least three times per group, and animal experiments included at least six mice per group. Western blot bands were analyzed using ImageJ software for normalized grayscale analysis. Statistical analysis was performed using GraphPad Prism software. If the data conformed to a normal distribution, the Student's t-test was used. Comparisons between multiple groups were performed using one-way ANOVA. All statistical analyses were expressed as mean ± standard deviation (SD). P < 0.05 was considered statistically significant.

[0121] 6. Experimental Results

[0122] like Figure 4 As shown in the figure, compared with the control group, the urine albumin / urine creatinine ratio of diabetic nephropathy mice with macrophage LSR deficiency was significantly increased. Immunofluorescence staining results showed that ( Figure 5 ), the expression levels of podocyte marker proteins NPHS1, NPHS2, PODXL and WT1 in diabetic nephropathy mice with macrophage LSR deficiency were significantly lower than those in the control group. In addition, histological staining and electron microscopy results showed that ( Figure 6 ), diabetic nephropathy mice lacking macrophage LSR showed significant glomerular hypertrophy, significant mesangial matrix deposition, significant GBM thickening, and disappearance of foot process fusion, suggesting podocyte damage. We also detected changes in serum creatinine levels, and the results showed that the serum creatinine level in diabetic nephropathy mice lacking macrophage LSR was significantly increased ( Figure 7 By real-time fluorescence quantitative PCR and Western blotting, we found that the absence of macrophage LSR led to a significant increase in the expression of renal injury molecules KIM-1, NGAL, and renal fibrosis molecule a-SMA in diabetic nephropathy mice ( Figure 8 In addition, histological staining and immunofluorescence staining also confirmed the above experimental results ( Figure 9 and Figure 10 It is noteworthy that the serum LDL-C level in diabetic nephropathy mice lacking macrophage LSR was significantly higher than that in the control group, accompanied by a significant increase in ectopic lipid droplet deposition in the glomeruli and renal tubules ( Figure 11 and Figure 12 These results indicate that compared with the control group, the glomerular and tubular damage in diabetic nephropathy mice was aggravated after macrophage LSR deficiency.

[0123] Example 4

[0124] Bone marrow transplantation can alleviate renal damage in diabetic nephropathy caused by macrophage LSR deficiency.

[0125] 1. Diabetic Mouse Modeling Method

[0126] After single nephrectomy and STZ injection, blood glucose was tested in mice. A fasting blood glucose value higher than 16.7 mmol / L indicated a successful model.

[0127] 2. Bone Marrow Transplantation Treatment of Diabetic Mice

[0128] Donor mouse bone marrow cell extraction: After euthanasia of 8-week-old wild-type and KO mice, the femur and tibia were dissected, soaked in 75% alcohol for 5 minutes, and then soaked in PBS for 5 minutes. The bones were cut open at both ends and rinsed with sterile PBS. The collected cell suspension was filtered through a 40 μm filter and centrifuged at 500 g for 5 minutes. The supernatant was discarded, and red blood cell lysis buffer was added to the cell pellet for 3 minutes. The reaction was terminated by adding complete culture medium. The cells were centrifuged again, the supernatant was discarded, and the cells were resuspended in sterile PBS to a density of 1×10 7 cells / mL and place on ice until ready for use.

[0129] Preparation of bone marrow transplant recipient mice: One week before irradiation, recipient LSR - / - The mice drank sterile water containing gentamicin (0.4 g / L) and received X-ray irradiation (5.5 Gy, twice, 3 h apart). 6 h later, the donor mice (LSR) were injected via the tail vein. Ctrl Mice and Mouse) bone marrow cells 5×10 6 , forming chimeric mouse LSR Ctrl →LSR - / - Mice and Mice continued to drink gentamicin-containing water after irradiation, which was replaced with normal water after 2 weeks; and began to be fed high-cholesterol food 6 weeks after irradiation.

[0130] 3. Experimental Results

[0131] like Figure 13 As shown in the figure, compared with the control group, the urine albumin / urine creatinine ratio of diabetic nephropathy mice lacking macrophage LSR was significantly reduced after receiving wild-type mouse bone marrow transplantation. Immunofluorescence staining results showed that ( Figure 14 ), the expression levels of podocyte marker proteins NPHS1, NPHS2, PODXL and WT1 in diabetic nephropathy mice lacking macrophage LSR after receiving wild-type mouse bone marrow transplantation were significantly increased compared with the control group. In addition, histological staining and electron microscopy results showed that ( Figure 15 ), diabetic nephropathy mice lacking macrophage LSR showed no significant changes in glomerular volume, no obvious mesangial matrix deposition, normal GBM thickness, and clear and intact foot process structure after receiving wild-type mouse bone marrow transplantation, suggesting that podocyte damage was alleviated. We also detected changes in serum creatinine levels, and the results showed that serum creatinine levels in diabetic nephropathy mice lacking macrophage LSR were significantly reduced after receiving wild-type mouse bone marrow transplantation ( Figure 16 By real-time fluorescence quantitative PCR and Western blotting, we found that the expression of kidney injury molecules KIM-1, NGAL and renal fibrosis molecule a-SMA was significantly reduced in diabetic nephropathy mice lacking macrophage LSR after receiving wild-type mouse bone marrow transplantation ( Figure 17 In addition, histological staining and immunofluorescence staining also confirmed the above experimental results ( Figure 18 and Figure 19 In diabetic nephropathy mice lacking macrophage LSR, serum LDL-C levels were significantly lower than those in the control group after bone marrow transplantation, and ectopic deposition of lipid droplets in glomeruli and renal tubules was significantly reduced ( Figure 20 and Figure 21 These results indicate that, compared with control mice, glomerular and tubular damage was alleviated in diabetic nephropathy mice lacking macrophage LSR after receiving wild-type mouse bone marrow transplantation.

[0132] Example 5

[0133] LSR deficiency in macrophages promotes inflammatory responses through activation of the YAP signaling pathway.

[0134] 1. Cell processing

[0135] (1) Extraction of peritoneal macrophages

[0136] To LSR Ctrl Mice and Mice were intraperitoneally injected with 4% thioglycolate medium (3 mL / mouse). Seventy-two hours later, the mice were sacrificed, and the peritoneal cavity was lavaged with 20 mL of PBS. The lavage fluid was collected and centrifuged (500 × g, 3 min). After resuspending in 1640 medium supplemented with 10% FBS, the cells were cultured in a 37°C, 5% CO2 incubator. Non-adherent cells were discarded after 1 hour to obtain peritoneal macrophages.

[0137] (2) Extraction and induction of bone marrow-derived macrophages

[0138] Extract LSR Ctrl Mice and Mouse bone marrow cells were lysed with red blood cell lysis buffer for 2 minutes, resuspended in 1640 medium containing 10% FBS, and inoculated into culture dishes for 6 days. Fresh medium was replaced every 3 days. M-CSF cytokine was added on the first and third days of culture to obtain bone marrow-derived macrophages.

[0139] (3) Extraction of kidney-resident macrophages

[0140] After the mouse is anesthetized, 20 mL of pre-cooled PBS is perfused through the left ventricle until the kidney becomes pale (to remove circulating blood cells). The kidney is removed and placed in PBS on ice. The capsule and fat are removed, weighed, and minced into 1-2 mm pieces. 3 Small pieces. Transfer the tissue pieces to a 15mL centrifuge tube, add preheated collagenase IV + DNase I mixture (5mL / kidney), and digest at 37℃ with shaking for 20-30min. Then add an equal volume of DMEM containing 10% FBS to terminate the digestion and let it stand on ice for 5min. Filter through 70μm and 40μm cell sieves in turn and collect the filtrate. Centrifuge at 400g for 5min and discard the supernatant. Add 2mL ACK lysis buffer, lyse on ice for 1min, and immediately terminate with PBS. Then wash twice with PBS and resuspend in PBS + 0.5% BSA. Next, enrich the macrophages by slowly adding the cell suspension to the Percoll gradient (30% / 70%) and centrifuge at 800g for 20min. Aspirate the interface layer (monocyte / macrophage enriched layer) and wash with PBS. Finally, perform flow cytometry sorting.

[0141] 2. RNA Extraction and Real-time Quantitative PCR

[0142] Same as Example 1.

[0143] 3. Western blot

[0144] Same as Example 1.

[0145] 4. Experimental results

[0146] Western blotting results showed that compared with the control group, macrophage LSR deficiency led to increased YAP protein expression and decreased p-YAP levels ( Figure 22-24 A). In addition, real-time quantitative PCR showed that the expression levels of YAP target genes and pro-inflammatory cytokines in the experimental group were significantly increased compared with the control group ( Figure 22-24 B) These results indicate that LSR deficiency in macrophages promotes the secretion of inflammatory factors through YAP activation.

[0147] Example 6

[0148] Macrophage LSR deficiency reduces LDL-C uptake.

[0149] 1. Dil-LDL uptake experiment in mice

[0150] Dilute Dil-LDL with sterile PBS to a working concentration (e.g., 100 μg for a 20 g mouse) and inject it into the mouse via retroorbital vein. Four hours after injection, the mouse is anesthetized and sacrificed, and blood, liver, kidney, and peritoneal macrophages are quickly removed. The sacrificed mouse is perfused via the left ventricle with 20 mL of PBS (4°C) to reduce interference from residual Dil-LDL in the blood vessels. The sample is then embedded in OCT and frozen sections are prepared.

[0151] 2. In vitro Dil-LDL uptake experiment

[0152] Mouse peritoneal macrophages and bone marrow-derived macrophages were extracted and plated in 24-well plates to a confluence of approximately 90%. 20 μg / mL Dil-LDL was added and incubated for 4 hours. The culture medium was collected and the fluorescence intensity was measured using a multifunctional fluorescence microplate reader to determine the amount of Dil-LDL remaining in the supernatant. The cells were lysed, and the fluorescence intensity of the lysate was measured to determine the amount of Dil-LDL taken up. The protein concentration was determined for calibration.

[0153] 3. Induction of differentiation of human THP-1 macrophages

[0154] The suspended THP-1 cells were centrifuged (300 g, 5 min) and resuspended in complete culture medium to adjust the density to 2-5×10 5 cells / mL. Next, cells were seeded in six-well plates to avoid overcrowding. PMA was added to a final concentration of 100 ng / mL to induce differentiation. After 48 hours of differentiation, the PMA-containing medium was aspirated and the cells were gently washed twice with pre-warmed PBS (to remove non-adherent cells and residual PMA). Fresh complete medium (without PMA) was added and cultured for an additional 24 hours to stabilize the phenotype.

[0155] 4. Construction of human THP-1 macrophages overexpressing LSR

[0156] Concentrated viral particles, pLVX-LSR-1, were added to differentiated THP-1 macrophages at an MOI of 10. 8 μg / mL polybrene was also added, gently mixed, and incubated in a 37°C, 5% CO2 incubator. After 4 hours, the medium was replaced with fresh RPMI 1640 supplemented with 10% fetal bovine serum. Culture was continued for 48 hours before subsequent testing.

[0157] 5. The LSR overexpression virus pLVX-LSR-1 was constructed using the following method:

[0158] ① Construction of plasmid

[0159] a) Obtain target gene: The coding sequence of mouse gene LSR was obtained from human cDNA library by PCR amplification. The coding sequence of human gene LSR is

[0160] SEQ ID NO.1: https: / / www.ncbi.nlm.nih.gov / nuccore / NM_001385215.1;

[0161] Specific primers were designed, an EcoRI restriction site was added to the 5' end of the upstream primer, and a SmaI restriction site was added to the 5' end of the downstream primer. The primer sequences were verified to be correct before synthesis.

[0162] b) Vector Treatment: Double digest the pLVX-Puro vector with EcoRI and SmaI. The digestion system is as follows: 1 μg of pLVX vector, 1 μL of EcoRI, 1 μL of SmaI, 2 μL of 10× Buffer, and ddH2O to 20 μL. Incubate at 37°C for 2 h. After digestion, perform agarose gel electrophoresis to recover the linearized vector fragment.

[0163] c) Ligation: Mix the recovered target gene fragment with the linearized pLVX-Puro vector at a molar ratio of 3:1. Add 1 μL of T4 DNA ligase, 2 μL of 10× T4 DNA ligase buffer, and make up to 20 μL with ddH2O. Ligate overnight at 16°C. d) Transformation and Screening: Transform the ligation product into competent E. coli DH5α cells, spread onto LB solid medium containing ampicillin, and incubate overnight at 37°C. A single colony was selected and inoculated into LB liquid medium containing ampicillin. Incubate at 37°C with shaking overnight. The plasmid was extracted and verified by double enzyme digestion and sequencing to identify the correct recombinant plasmid, pLVX-LSR-1.

[0164] ②293T cell culture

[0165] 293T cells were cultured in DMEM supplemented with 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin in a 37°C, 5% CO2 incubator. When the cell density reached 80%-90%, cells were subcultured using 0.25% trypsin and passaged at a 1:3 ratio.

[0166] ③ Virus packaging and concentration

[0167] a) Co-transfection of 293T cells: 293T cells in logarithmic growth phase were seeded into 6-well plates. Transfection was performed when the cell density reached 70%-80%. Using lipofectamine transfection, the recombinant plasmid pLVX-LSR-1 was mixed with the packaging plasmids psPAX2 and pMD2.G at a ratio of 4:3:1. Lipofectamine reagent was added and the medium was replaced with fresh DMEM 6 hours after transfection.

[0168] b) Collecting viral supernatant: 48 h and 72 h after transfection, collect the cell culture supernatant, respectively, and filter with a 0.45 μm filter to remove cell debris.

[0169] c) Virus concentration: Transfer the filtered viral supernatant to an ultracentrifuge tube and ultracentrifuge at 25,000 rpm at 4°C for 2 h. Discard the supernatant and resuspend the viral pellet in an appropriate amount of PBS to obtain a concentrated viral solution.

[0170] ④ Infection and induction of adherent THP-1 macrophages

[0171] 6. Experimental Results

[0172] By injecting Dil-LDL into mice, we observed that the amount of residual Dil-LDL in the liver, kidney and serum of mice with macrophage LSR deficiency was significantly higher than that in the control group ( Figure 25 AC). In addition, immunofluorescence staining also demonstrated that the amount of Dil-LDL remaining in the liver and kidneys of mice with LSR deficiency in macrophages was significantly higher than that in the control group ( Figure 25 It is worth noting that the in vitro experimental results are consistent with the in vivo experiments. At the cellular level, we observed that LDL uptake was significantly reduced after macrophage LSR deficiency, as shown by a significant increase in the residual Dil-LDL content in the supernatant and a significant decrease in the residual Dil-LDL content in the cell lysate compared with the control group ( Figure 26 On the contrary, if LSR is overexpressed in macrophages, we will find that compared with the control group, the residual Dil-LDL content in the supernatant is significantly reduced and the residual Dil-LDL content in the cell lysate is significantly increased ( Figure 27 The above results indicate that LSR knockout in macrophages can significantly inhibit lipoprotein uptake.

[0173] Example 7

[0174] Macrophage LSR mediates LDL-C internalization in a clathrin-dependent manner.

[0175] 1. Immunofluorescence staining

[0176] Same as Example 2.

[0177] 2. Experimental results

[0178] To investigate the LSR-mediated LDL endocytosis process, we co-stained bone marrow-derived macrophages (BMDMs) with LSR and various organelle markers after adding DiI-LDL. Studies have shown that receptor-mediated LDL endocytosis initiates very rapidly, with almost all receptor-bound lipoproteins internalized within a short period of time. This study found that DiI-LDL co-localized with LSR spots and clathrin 1 minute after DiI-LDL was added to the culture medium. Figure 28 A). At 10-15 minutes, LSR partially co-localized in the early endosomes marked by EEA1 and the late endosomes marked by Rab7 ( Figure 28 B) After 15-20 minutes, some LSRs were sorted into the recycling endosomes labeled by Rab11, while DiI-LDL and some LSRs were retained in the late endosome and lysosomal degradation pathways ( Figure 28 C). After 20 minutes of incubation, LSR and DiI-LDL almost had no colocalization, and LSR was redistributed on the cell membrane ( Figure 28 D), suggesting that LSR in macrophages can recycle to the cell membrane and resume physiological functions. These results indicate that macrophages can undergo clathrin-dependent LSR internalization in the presence of LDL.

[0179] The present study found that macrophage LSR deficiency aggravated STZ-induced diabetic nephropathy renal damage by reducing the uptake of low-density lipoprotein and increasing the secretion of proinflammatory cytokines. Conversely, bone marrow transplantation experiments revealed that when macrophage LSR expression was restored, STZ-induced diabetic nephropathy glomerular and tubular damage was alleviated, which could effectively inhibit the occurrence and development of diabetic nephropathy (such as Figure 29 shown).

[0180] It should be noted that, in this article, the terms "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or apparatus that includes a series of elements includes not only those elements, but also includes other elements not explicitly listed, or also includes elements that are inherent to such process, method, article or apparatus.

[0181] The foregoing description is intended only to provide specific embodiments of the present invention, which will enable those skilled in the art to understand and implement the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention is not intended to be limited to the embodiments described herein, but is to be construed in the widest manner consistent with the principles and novel features disclosed herein.

Claims

1. Use of LSR gene and / or LSR protein in macrophages in the preparation or screening of drugs for preventing, alleviating, adjuvant treatment or / and treating diabetic nephropathy.

2. Use of a promoter of LSR gene and / or LSR protein in macrophages in the preparation of a drug for preventing, alleviating, adjuvant therapy or / and treating diabetic nephropathy, characterized in that: The promoter is a substance that can enhance the expression and / or activity and / or function of the LSR gene and / or LSR protein.

3. The use according to claim 2, characterized in that The LSR protein promoter includes substances that target and regulate the expression and / or activity of LSR genes and / or proteins by regulating signal pathways.

4. The use according to claim 2, characterized in that The promoter includes: a recombinant expression vector containing an LSR gene or a gene fragment with more than 90% homology to the LSR gene, a nucleic acid molecule capable of upregulating the expression of the LSR gene and / or LSR protein, a carbohydrate, a lipid, a small molecule chemical drug, an antibody drug, a polypeptide, a protein or at least one of a virus.

5. The use according to claim 4, characterized in that The recombinant expression vector includes any one of a vector-based eukaryotic expression plasmid, adenovirus, adeno-associated virus, lentivirus, retrovirus, baculovirus, herpes virus, pseudorabies virus, LNP liposome, microinjection technology, gene editing system elements or homologous recombination vector that specifically targets the LSR gene.

6. A drug, characterized in that The drug comprises at least one of the LSR gene and / or LSR protein according to claim 1, or the expression promoter of the LSR gene and / or LSR protein according to any one of claims 2 to 5, and uses them as the main functional components of the drug.

7. The drug according to claim 6, characterized in that The drug also includes pharmaceutically acceptable excipients, which include at least one of a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, a surfactant, an adsorption carrier, and a lubricant. The drug is in the form of any of tablets, capsules, powders, pills, granules, solutions, suspensions, syrups, injections, suppositories, inhalants, and sprays.

8. The medicine according to claim 7, characterized in that The mass percentage of the functional component in the medicine is 1%-99%.

9. Use of a reagent for detecting the expression of LSR gene and / or protein in macrophages in the preparation of a product for auxiliary diagnosis, screening or evaluation of diabetic nephropathy.

10. The use according to claim 9, characterized in that The product includes any one of a chip, a diagnostic reagent, and a diagnostic kit; the detection sample of the product is any one of a cell or whole blood; the product contains an antibody that specifically binds to the LSR protein or a peptide segment of the LSR protein, or contains primers that specifically amplify the LSR gene, or contains a probe that specifically detects the LSR gene.

Citation Information

Cited By

  • Application of detection biomarker in preparation of product for diagnosing or treating high-salt diet kidney injury

    CN121114458A